BioXell S.p.A. Announces Phase II Results For Elocalcitol In Overactive Bladder
Published: May 11, 2006
BioXell S.p.A. today reported clear efficacy of its lead compound, Elocalcitol (previously BXL628), in a Phase II study in Overactive Bladder (OAB). In the recently concluded trial, Elocalcitol demonstrated numerical superiority on its primary endpoint and statistically significant efficacy in several clinically relevant subgroups compared to placebo. The study, a placebo-controlled, double-blind, 3-month trial involving 114 patients with OAB, also showed that Elocalcitol continues to be extremely well tolerated, with an adverse event profile comparable to placebo.